FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes.

Asmerom Tesfamariam SengalAnn-Marie PatchCameron E SnellDeborah S SmithSamuel C Y LeungAline Talhouk Elizabeth D Williams Jessica N McAlpinePamela M Pollock

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

FGFR2c expression appears an independent prognostic biomarker in patients with EEC and further discerns the outcomes within grade 3 tumors, ESMO high-risk groups, as well as within the MMRd and p53wt subtypes. FGFR2c inclusion into future molecular subtyping can further refine risk stratification of EEC.

Keyphrases

poor prognosis
endometrial cancer
long non coding rna
stem cells
bone marrow
single molecule
adipose tissue
skeletal muscle
weight loss
glycemic control